Creating a new treatment to remove amyloid deposits in patients with systemic amyloidosis
Development of a Theranostic Immunotherapy for Systemic Amyloidosis
This study is testing a new treatment that uses special antibodies to help your immune system remove harmful amyloid deposits from your body if you have systemic amyloidosis, with the hope of improving your health and making future treatments more effective.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tennessee Health Sci Ctr NIH-funded |
| Lab location | 1 site (Memphis, United States) |
| Project ID | NIH-10792590 on NIH RePORTER |
What this research studies
This research focuses on developing a novel immunotherapy that targets and removes amyloid deposits from tissues in patients suffering from systemic amyloidosis. The approach involves using specially designed antibodies, known as peptibodies, which can bind to amyloid and recruit immune cells to clear it from the body. By utilizing molecular imaging techniques, the researchers aim to enhance the selection of patients for clinical trials and improve treatment outcomes. The ultimate goal is to create a therapy that not only reduces the production of amyloid-forming proteins but also effectively eliminates existing amyloid deposits.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with systemic amyloidosis who have significant amyloid deposits affecting their organs.
Not a fit: Patients who do not have systemic amyloidosis or those with early-stage disease without significant amyloid burden may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly improve the survival and quality of life for patients with systemic amyloidosis by effectively clearing harmful amyloid deposits from their tissues.
How similar studies have performed: Previous research has shown success with similar immunotherapy approaches in targeting amyloid deposits, indicating a promising avenue for treatment.
Where this research is happening
Memphis, United States
- University of Tennessee Health Sci Ctr — Memphis, United States (Active)
Researchers
- Principal investigator: Wall, Jonathan S — University of Tennessee Health Sci Ctr
- Study coordinator: Wall, Jonathan S
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.